Summary
This a phase II clinical trial for patients with advanced papillary kidney cancer (renal cell carcinoma), which compares the use of cabozantinib alone versus cabozantinib in combination with atezolizumab.
Description
- Condition: Metastatic papillary renal cell carcinoma (PRCC).
- Arm I: Patients receive cabozantinib orally once daily.
- Arm II: Patients receive cabozantinib orally once daily and atezolizumab intravenously once per cycle.
- Trial design: Participants are randomly assigned to one of the two arms. The primary goal is to compare the effects of the two treatments.
- Cabozantinib: This is a kinase inhibitor designed to block the signals that cause tumor cells to multiply.
- Atezolizumab: This is a monoclonal antibody used in immunotherapy that helps the body's immune system target and attack cancer cells.
Principal Investigator
Kok Hoe Chan
Study Coordinator
Lisa Luikart
Research Contact
Lisa Luikart
lisa.luikart@vandaliahealth.org
Phone Clinical Trials Center / Cancer Center 304.388.9944
Departments
Sex
All
Age
18+
NCT Number
NCT05411081
IRB Number
25-1211
Phase(s)
2